Side effects of the calcineurin inhibitor, such as new-onset diabetes after kidney transplantation.
New-onset diabetes after transplantation (NODAT) is one of the frequent complications following kidney transplantation. Patients were randomized to receive cyclosporine A- or tacrolimus-based immunosuppression. Fasting and oral glucose tolerance tests were performed, and the patients were assigned to one of the following three groups based on the results: normal, impaired fasting glucose/impaired glucose tolerance (IFG/IGT), or NODAT. NODAT developed in 14% of patients receiving cyclosporine A-based immunosuppression and in 26% of patients taking tacrolimus (p = 0.0002). Albumin levels were similar, but uric acid level (p = 0.002) and the age of the recipient (p = 0.003) were significantly different comparing the diabetic and the normal groups. Evaluation of tissue samples revealed that acute cellular rejection (ACR) and interstitial fibrosis/tubular atrophy (IF/TA) were significantly different in the NODAT group. The pathological effect of new-onset diabetes after kidney transplantation can be detected in the morphology of the renal allograft earlier, before the development of any sign of functional impairment.
['Borda|Bernadett|B|', 'Lengyel|Cs|C|', 'Várkonyi|T|T|', 'Kemény|E|E|', 'Ottlakán|A|A|', 'Kubik|A|A|', 'Keresztes|Cs|C|', 'Lázár|Gy|G|']
D000328:Adult D000367:Age Factors D000368:Aged D001284:Atrophy D001706:Biopsy D001786:Blood Glucose D019703:Calcineurin D065095:Calcineurin Inhibitors D016572:Cyclosporine D003920:Diabetes Mellitus D005215:Fasting D005260:Female D005355:Fibrosis D005951:Glucose Tolerance Test D006084:Graft Rejection D006801:Humans D006814:Hungary D007166:Immunosuppressive Agents D015994:Incidence D007668:Kidney D016030:Kidney Transplantation D008297:Male D008875:Middle Aged D012307:Risk Factors D016559:Tacrolimus D013997:Time Factors
calcineurin inhibitors new-onset diabetes mellitus after kidney transplantation protocol biopsy